- CFO Spotlights
- Profiles
- Matt David, M.D.
Profile
Matt David, M.D.
Chief Financial Officer and principal financial officer, Actinium Pharmaceuticals, Inc.
In the seat. First published here October 28, 2026; built from records as of October 28, 2026.
Matt David, M.D. has been Chief Financial Officer and principal financial officer of Actinium Pharmaceuticals, Inc. since October 14, 2026, according to the company's filing of October 15, 2026.1
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) Pharmaceutical Preparations | Chief Financial Officer and principal financial officer | In the seat |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- October 14, 2026effective
Actinium Pharmaceuticals, Inc. appointed Matt David, M.D. as Chief Financial Officer and principal financial officer, effective October 14, 2026.
On October 14, 2026, Matt David, M.D., age 49, commenced service as Chief Financial Officer and principal financial officer of Actinium Pharmaceuticals, Inc. (the “Company”).
[1] Filing by Actinium Pharmaceuticals, Inc., filed with the SEC on October 15, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Current report filed with the SEC, Actinium Pharmaceuticals, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed October 15, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or Matt David, M.D. wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.